ELB245 for 12 Weeks Versus 4mg Tolterodine in Patients With Incontinent Overactive Bladder (OAB)
Status:
Terminated
Trial end date:
2007-08-01
Target enrollment:
Participant gender:
Summary
This study is designed to determine the efficacy of escalating doses of ELB245 versus placebo
, when administered to patients with OAB and to compare the efficacy of escalating doses of
ELB245 versus the standard treatment tolterodine, when administered to patients with OAB.